Background Circle Background Circle
FDA approves prescription nasal spray to reverse opioid overdoses

FDA approves prescription nasal spray to reverse opioid overdoses

The Food and Drug Administration (FDA) approved a prescription nasal spray this week that can reverse opioid overdoses.

Opvee is an almefene hydrochloride nasal spray that is the first of its kind to be used to treat opioid overdoses in adults and children over the age of 12.

The FDA said that if the product is administered quickly, it can reduce the effects of opioid overdoses, including respiratory depression, sedation and low blood pressure.

“The agency continues to advance the FDA Overdose Prevention Framework and take actionable steps that encourage harm reduction by supporting the development of novel overdose reversal products,” FDA Commissioner Robert Califf said in a statement on Monday.

“On the heels of the FDA’s recent approval of the first over-the-counter opioid reversal agent, the availability of nalmefene nasal spray places a new prescription opioid reversal option in the hands of communities, harm reduction groups and emergency responders,” he added.

In March, the FDA for the first time approved a naloxone nasal spray, sold under the Narcan brand, for use without a prescription.

The FDA press release stated that drugs like fentanyl accounted for about 103,000 reported fatal overdoses in a 12-month period that ended in November 2022.

“In this overdose crisis, we are seeing fatalities that cut across demographics and patterns of drug use. There are unique populations and needs in different circumstances. We need more choices in our toolkit to help us respond, and importantly, broad access to those tools,” Nora Volkow, director of the National Institute on Drug Abuse, said in a statement.

“The FDA approval of intranasal nalmefene, after years of research from NIH and industry, is good news. Along with the other forms of overdose-reversing antidotes on the market, nalmefene can save lives. That’s the goal,” she added.

Copyright 2023 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Source link

You Might Also Like!
Closer look at marijuana illness CHS and top medical news of 2016

CBS News chief medical correspondent Dr. Jon LaPook takes a look at a marijuana-related health illness where diagnosis could be ENGAGE+

J&J Vaccine May Block Spread of Coronavirus, FDA Says

The Moderna and Pfizer vaccines were tested before the discovery of variants from the United Kingdom, South Africa, and Brazil, ENGAGE+

The Therapeutics and Politics of Medical Marijuana.

Dr. J. Michael Bostwick, Professor of psychiatry at Mayo Clinic in Rochester, MN, discusses his article appearing in the February ENGAGE+

Johnson and Johnson vaccine: FDA finds the single-shot jab safe

US regulators say Johnson and Johnson's single-shot vaccine is safe, and could be approved in days. Source link

Covid: France approves AstraZeneca vaccine for over-65s

Speaking on television, French Health Minister Olivier Véran said people with pre-existing conditions - such as high blood pressure or ENGAGE+

Formaldehyde in Hair Straighteners Prompts FDA Warning

FRIDAY, March 5, 2021 (HealthDay News) -- You might decide your frizzy locks aren't so bad after all, given a ENGAGE+

Opioid Use Among Older Adults

Part of getting older means that you may deal with aches and pain. To treat pain, your doctor may prescribe ENGAGE+

Breaking News: FDA Urges Pause of J&J COVID Vaccine

April 13, 2021 -- The FDA and CDC on Tuesday recommended that use of the Johnson & Johnson COVID-19 vaccine ENGAGE+